PSA and spironolactone;PSA et spironolactone

Progres en Urologie

Volumn 20, Issue 2, 2010, Pages 154-157

  Rybikowski, S ^a   Maurin, C ^a   Deturmeny, J ^a   Delaporte, V ^a   Lechevallier, E ^a   Coulange, C ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Antiandrogenic effects; Prostate cancer; PSA normalization; Spironolactone

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; SPIRONOLACTONE;

AGED; ARTICLE; BLOOD; CASE REPORT; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SPIRONOLACTONE;

EID: 75149192611     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2009.04.002     Document Type: Article

References (6)

1. Kossor D.C., Kominami S., Takemori S., and Colbi H.D. Role of the steroid 17 alpha-hydroxylase in spironolactone-mediated destruction of adrenal cytochrome P-450. Mol Pharmacol 40 (1991) 321-325
2. Siberti L., Kuhn J.-M., Rossi D., and Tostain J. Interactions médicamenteuses avec l'équilibre androgénique de l'homme adulte. Rapport AFU 2004. Prog Urol 14 (2004) 679-684
3. Négri C., Tosi F., Dorizzi R., FortunatoA, Spiazzi G.G., Castello R., et al. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab 85 (2000) 81-84
4. Guzelmeric K., Seker N., Unal O., and Turan C. High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill. Gynecol Endocrinol 19 (2004) 190-195
5. Walsh P.C., and Siiteri P.K. Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. J Urol 114 (1975) 254-256
6. Attard G., Reid A.H., Yap T.A., Raynaud F., Dowsett M., Settatree S., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4535-4536